dr. john hohneker is a biotechnology leader with deep experience leading research assets from discovery phase to clinical development and has advanced several drugs from pre-clinical evaluations through phase i-iv trials. his research interests include drug development experience in the pharmaceutical industry across a broad range of therapeutic areas including oncology, immunology, dermatology, rheumatology, and organ transplantation. he currently serves on the board of directors at aravive, evelo bioscience, and trishula therapeutics. previously he was ceo at anokion and president of research and development at forma therapeutics inc., both privately held biotechnology companies. prior to forma, he was senior vice president and global head of development for immunology and dermatology at novartis ag. prior to joining novartis, he held positions of increasing responsibility at glaxo wellcome and its legacy company, burroughs wellcome. dr. hohneker completed his md from the university of medicine and dentistry of new jersey at rutgers robert wood johnson medical school, his residency at north carolina memorial hospital, and his postdoctoral fellowship at ucsd medical center & university of north carolina in hematology and oncology.
www.oncusptx.com是上海昂阔医药有限公司旗下网站，网站成立于2021年1月15日，该网站属于综合其他行业。网站主要内容为：oncusp therapeutics,oncusp等。网站前端技术使用swiper,jquery，网站后端技术使用microsoft asp.net,windows server,iis。网站已经通过工信部备案，备案号为： 沪icp备2021016389号。已开启gzip压缩。
